Cost-effectiveness analysis of elranatamab versus physician&#39;s choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan.

Tecvayli (teclistamab-cqyv) - Genmab, J&J

Abecma (idecabtagene vicleucel) - BMS

Elrexfio (elranatamab-bcmm) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/42709039

Akira Yuasa; Hiroyuki Matsuda; Kengo Hatsuyama; Kenshi Suzuki; Marco DiBonaventura; Mitsuhiro Nagano; Patrick Hlavacek; Yoichi Kamei

Sep 9, 2026